Risedronate Sodium Patent Expiration
Risedronate Sodium is Used for prevention and treatment of osteoporosis, including in postmenopausal women, as well as for treating Paget's disease. It was first introduced by Allergan Pharmaceuticals International Ltd
Risedronate Sodium Patents
Given below is the list of patents protecting Risedronate Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Atelvia | US7645459 | Dosage forms of bisphosphonates | Jan 09, 2028 | Apil |
| Atelvia | US7645460 | Dosage forms of risedronate | Jan 09, 2028 | Apil |
| Atelvia | US8246989 | Dosage forms of bisphosphonates |
Jan 16, 2026
(Expired) | Apil |
| Actonel |
US7192938 (Pediatric) | Method of treatment using bisphosphonic acid |
Nov 06, 2023
(Expired) | Apil |
| Actonel |
US7718634 (Pediatric) | Method of treatment using bisphosphonic acid |
Nov 06, 2023
(Expired) | Apil |
| Actonel | US7192938 | Method of treatment using bisphosphonic acid |
May 06, 2023
(Expired) | Apil |
| Actonel | US7718634 | Method of treatment using bisphosphonic acid |
May 06, 2023
(Expired) | Apil |
| Actonel |
US6465443 (Pediatric) | Method for inhibiting bone resorption |
Feb 14, 2019
(Expired) | Apil |
| Actonel |
US5994329 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Apil |
| Actonel |
US6015801 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Apil |
| Actonel |
US6432932 (Pediatric) | Method for inhibiting bone resorption |
Jan 17, 2019
(Expired) | Apil |
| Actonel |
US6165513 (Pediatric) | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec 10, 2018
(Expired) | Apil |
| Actonel | US6465443 | Method for inhibiting bone resorption |
Aug 14, 2018
(Expired) | Apil |
| Actonel | US5994329 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Apil |
| Actonel | US6015801 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Apil |
| Actonel | US6432932 | Method for inhibiting bone resorption |
Jul 17, 2018
(Expired) | Apil |
| Actonel | US6165513 | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun 10, 2018
(Expired) | Apil |
| Actonel |
US5583122 (Pediatric) | Pharmaceutical compositions containing geminal diphosphonates |
Jun 10, 2014
(Expired) | Apil |
| Atelvia |
US5583122 (Pediatric) | Pharmaceutical compositions containing geminal diphosphonates |
Jun 10, 2014
(Expired) | Apil |
| Atelvia | US5622721 | Dosage forms of risedronate |
Apr 21, 2014
(Expired) | Apil |
| Actonel | US5583122 | Pharmaceutical compositions containing geminal diphosphonates |
Dec 10, 2013
(Expired) | Apil |
| Atelvia | US5583122 | Pharmaceutical compositions containing geminal diphosphonates |
Dec 10, 2013
(Expired) | Apil |
Risedronate Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Risedronate Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy | Harbin Medical University | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |